Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Olutasidenib (Rezlidhia) for acute myeloid leukemia.

The Medical letter on drugs and therapeutics - 3 Apr 2023

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leukemia, Myeloid, Acute
Share to Mutation
Share to Pyridines
Share to Quinolines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37020343
DOI: 10.58347/tml.2023.1673e

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Olutasidenib (Rezlidhia) for acute myeloid leukemia.PMID 37020343Read ↗

Olutasidenib: First Approval.Semantic proximity Read ↗

Quizartinib (Vanflyta) for acute myeloid leukemia.Semantic proximity Read ↗

[Advancesin FLT3 inhibitors for acute myeloid leukemia].Semantic proximity Read ↗

[State of the art in the treatment of chronic leukemias].Semantic proximity Read ↗

In brief: Two new drugs for AML.Semantic proximity Read ↗

FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation.Semantic proximity Read ↗

Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experienceSemantic proximity Read ↗

Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.Semantic proximity Read ↗

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.Semantic proximity Read ↗

BCL2/MDM2 Inhibitor Combo Effective in AMLSemantic proximity Read ↗

Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemiaSemantic proximity Read ↗

Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.